Ren YJ, Yang L, Zhai ZH. Clinical value of inhibition of vascular endothelial growth factor in primary hepatocellular carcinoma after transcatheter arterial chemoembolization.
Shijie Huaren Xiaohua Zazhi 2010;
18:1582-1587. [DOI:
10.11569/wcjd.v18.i15.1582]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Vascular endothelial growth factor (VEGF) is a well-known potent angiogenic factor that correlates with tumor invasion and metastasis. Primary hepatocellular carcinoma (PHC) is a common highly malignant vascular tumor with a very high mortality. Angiogenesis is considered to be important for PHC progression. Transarterial chemoembolization (TACE) has been proved to be effective for unresectable PHC. This paper aims to make a literature review of the recent advances in understanding the clinical value of inhibition of VEGF in PHC after interventional therapy.
Collapse